A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2013
At a glance
- Drugs Temsirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.